Episode
Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- Published
- Jul 15, 2026
- Duration seconds
- 7279
- Processing state
not_requested- Canonical source
- https://oncologytoday.captivate.fm/episode/6133-asco2026-ovarian
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/ovarian-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/ovarian-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00) Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40) Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41) Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12) Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35) Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications